GEN-001
/ Genocea
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
October 15, 2021
Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer
(clinicaltrials.gov)
- P=N/A; N=40; Not yet recruiting; Sponsor: Korean Cancer Study Group
Clinical • New trial • Colorectal Cancer • Gastrointestinal Cancer • Immune Modulation • Immunology • Inflammation • Oncology • Rectal Cancer • Solid Tumor • CD4 • CD8
October 23, 2020
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
(clinicaltrials.gov)
- P1; N=93; Recruiting; Sponsor: Genome & Company
Clinical • Combination therapy • New P1 trial • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer
November 16, 2020
"#GenomeCompany's #IimmunoAntiCancerMicrobiome treatment #GEN001 clinically approved by the Ministry of Food and Drug Safety https://t.co/ppiEhcEwEZ"
(@1stOncology)
Clinical • Oncology
July 22, 2020
Genocea Announces Private Placement Financing of Up to $80 Million
(GlobeNewswire)
- "Genocea intends to use the net proceeds from this private placement to fund continued clinical and program development of its neoantigen vaccine GEN-009 and its neoantigen cell therapy GEN-011, as well as for working capital and other general corporate purposes."
Financing • Oncology
1 to 4
Of
4
Go to page
1